Synthetic vectors for activating the driving axis of ferroptosis

Jun Jiang, Lili Yang, Qianqian Xie, Xi Liu, Jie Jiang, Jie Zhang, Shuping Zhang, Huizhen Zheng, Wenjie Li, Xiaoming Cai, Sijin Liu () and Ruibin Li ()
Additional contact information
Jun Jiang: Soochow University
Lili Yang: Soochow University
Qianqian Xie: Soochow University
Xi Liu: Soochow University
Jie Jiang: Soochow University
Jie Zhang: Shandong First Medical University & Shandong Academy of Medical Sciences
Shuping Zhang: Shandong First Medical University & Shandong Academy of Medical Sciences
Huizhen Zheng: Soochow University
Wenjie Li: Soochow University
Xiaoming Cai: Soochow University
Sijin Liu: Shandong First Medical University & Shandong Academy of Medical Sciences
Ruibin Li: Soochow University

Nature Communications, 2024, vol. 15, issue 1, 1-15

Abstract: Abstract Ferroptosis is a promising strategy for cancer therapy, with numerous inhibitors of its braking axes under investigation as potential drugs. However, few studies have explored the potential of activating the driving axes to induce ferroptosis. Herein, phosphatidylcholine peroxide decorating liposomes (LIPPCPO) are synthesized to induce ferroptosis by targeting divalent metal transporter 1 (DMT1). LIPPCPO is found to boost lysosomal Fe2+ efflux by inducing cysteinylation of lysosomal DMT1, resulting in glutathione peroxidase 4 (GPX4) suppression, glutathione depletion and ferroptosis in breast cancer cells and xenografts. Importantly, LIPPCPO induced ferroptotic cell death is independent of acquired resistance to radiation, chemotherapy, or targeted agents in 11 cancer cell lines. Furthermore, a strong synergistic ferroptosis effect is observed between LIPPCPO and an FDA-approved drug, artesunate, as well as X rays. The formula of LIPPCPO encapsulating artesunate significantly inhibits tumor growth and metastasis and improves the survival rate of breast cancer-bearing female mice. These findings provide a distinct strategy for inducing ferroptosis and highlight the potential of LIPPCPO as a vector to synergize the therapeutic effects of conventional ferroptosis inducers.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52312-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52312-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52312-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().